文献速递乳腺癌

HER2低表达阳性乳腺癌的临床与分子特征:四项前瞻性新辅助临床试验个体患者数据汇总分析

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
PubMed 文献 · Lancet Oncol · 2021-07-09

该汇总分析纳入四项前瞻性新辅助临床试验中2310例HER2非扩增原发性乳腺癌患者,比较HER2低表达阳性与HER2零表达肿瘤的临床分子特征、新辅助化疗反应及预后。结果显示HER2低表达阳性肿瘤激素受体阳性比例更高、病理完全缓解率更低但生存期更长,尤其在激素受体阴性亚组中差异显著。

要点

  • HER2低表达阳性肿瘤病理完全缓解率显著低于HER2零表达肿瘤,尤其在激素受体阳性亚组。
  • HER2低表达阳性肿瘤生存期显著优于HER2零表达肿瘤,尤其在激素受体阴性亚组。

核心结论

  • HER2低表达阳性肿瘤可通过标准化免疫组化识别为乳腺癌新亚组,具有独特生物学特征、治疗反应和预后差异。

研究设计与样本

  • 汇总分析四项前瞻性新辅助临床试验(GeparSepto、GeparOcto、GeparX、Gain-2 neoadjuvant)的个体患者数据,纳入2310例HER2非扩增原发性乳腺癌患者,接受新辅助联合化疗。
  • HER2低表达阳性定义为免疫组化1+或2+且原位杂交阴性,HER2零表达定义为免疫组化0,依据ASCO/CAP指南。

关键数值与推荐

  • HER2低表达阳性定义:免疫组化1+或免疫组化2+且原位杂交阴性;HER2零表达定义:免疫组化0。

临床怎么用

  • 基于标准化免疫组化识别HER2低表达阳性乳腺癌亚组,有助于细化诊断和未来治疗策略。
  • HER2低表达阳性且激素受体阴性肿瘤对化疗抵抗且预后差异显著,可能需新型抗体药物偶联物等治疗。
  • HER2低表达状态应结合激素受体状态综合评估新辅助化疗反应和预后。

局限性

  • 生存数据仅来自1694例患者(除GeparX外所有试验),非全部2310例。
  • 汇总分析设计,尽管前瞻性试验,可能存在未控制混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of anti-HER2 antibody-drug conjugates opens new therapeutic options for patients with breast cancer, including patients with low expression of HER2. To characterise this new breast cancer subtype, we have compared the clinical and molecular characteristics of HER2-low-positive and HER2-zero breast cancer, including response to neoadjuvant chemotherapy and prognosis. METHODS: In this pooled analysis of individual patient data, we evaluated a cohort of 2310 patients with HER2-non-amplified primary breast cancer that were treated with neoadjuvant combination chemotherapy in four prospective neoadjuvant clinical trials (GeparSepto, NCT01583426; GeparOcto, NCT02125344; GeparX, NCT02682693; Gain-2 neoadjuvant, NCT01690702) between July 30, 2012, and March 20, 2019. Central HER2 testing was done prospectively before random assignment of participants in all trials. HER2-low-positive status was defined as immunohistochemistry (IHC) 1+ or IHC2+/in-situ hybridisation negative and HER2-zero was defined as IHC0, based on the American Society of Clinical Oncology/College of American Pathologists guidelines. Disease-free survival and overall survival data were available for 1694 patients (from all trials except GeparX) with a median follow-up of 46·6 months (IQR 35·0-52·3). Bivariable and multivariable logistic regression models and Cox-proportional hazards models were performed based on a predefined statistical analysis plan for analysis of the endpoints pathological complete response, disease-free survival, and overall survival. FINDINGS: A total of 1098 (47·5%) of 2310 tumours were HER2-low-positive and 1212 (52·5%) were HER2-zero. 703 (64·0%) of 1098 patients with HER2-low-positive tumours were hormone receptor positive, compared with 445 (36·7%) of 1212 patients with HER2-zero tumours (p<0.0001). HER2-low-positive tumours had a significantly lower pathological complete response rate than HER2-zero tumours (321 [29·2%] of 1098 vs 473 [39·0%] of 1212, p=0·0002). Pathological complete response was also significantly lower in HER2-low-positive tumours versus HER2-zero tumours in the hormone receptor-positive subgroup (123 [17·5%] of 703 vs 105 [23·6%] of 445, p=0·024), but not in the hormone receptor-negative subgroup (198 [50·1%] of 395 vs 368 [48·0%] of 767, p=0·21). Patients with HER2-low-positive tumours had significantly longer survival than did patients with HER2-zero tumours (3-year disease-free survival: 83·4% [95% CI 80·5-85·9] vs 76·1% [72·9-79·0]; stratified log-rank test p=0·0084; 3-year overall survival: 91·6% [84·9-93·4] vs 85·8% [83·0-88·1]; stratified log-rank test p=0·0016). Survival differences were also seen in patients with hormone receptor-negative tumours (3-year disease-free survival: 84·5% [95% CI 79·5-88·3] vs 74·4% [70·2-78.0]; stratified log-rank test p=0·0076; 3-year overall survival: 90·2% [86·0-93·2] vs 84·3% [80·7-87·3], stratified log-rank test p=0·016), but not in patients with hormone receptor-positive tumours (3-year disease-free survival 82·8% [79·1-85·9] vs 79·3% [73·9-83·7]; stratified log-rank test p=0·39; 3-year overall survival 92·3% [89·6-94·4] vs 88·4% [83·8-91·8]; stratified log-rank test p=0·13). INTERPRETATION: Our results show that HER2-low-positive tumours can be identified as new subgroup of breast cancer by standardised IHC, distinct from HER2-zero tumours. HER2-low-positive tumours have a specific biology and show differences in response to therapy and prognosis, which is particularly relevant in therapy-resistant, hormone receptor-negative tumours. Our results provide a basis for a better understanding of the biology of breast cancer subtypes and the refinement of future diagnostic and therapeutic strategies. FUNDING: German Cancer Aid (Deutsche Krebshilfe).

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021. PMID: 34252375. doi:10.1016/S1470-2045(21)00301-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。